- KR₩76bn
- KR₩93bn
- KR₩137bn
- 44
- 71
- 48
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.56 | ||
| EV to EBITDA | 11.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.5% | ||
| Return on Equity | -1.82% | ||
| Operating Margin | 1.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 90,877.64 | 98,119.85 | 115,655.49 | 138,881.06 | 137,209.59 | n/a | n/a | 10.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -3.97 | -79.36 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
Directors
- Seung Pil Yoo CHM (73)
- Robert Yu PRE
- Jung Seon Park MDR (54)
- Jin Yong Song MDR (58)
- Han Guk Bae OTH (50)
- Gwang Jung Goh OTH (58)
- Jong Ryeol Ha OTH (49)
- Chang Gi Jeon OTH (82)
- Won Sang Yoo OTH (39)
- Yeong Gak Yoon DRC (63)
- Hyeong Moon Ahn NID (36)
- Seung An Kang NID (76)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 28th, 1941
- Public Since
- November 18th, 1975
- No. of Shareholders
- 23,979
- No. of Employees
- 243
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 16,182,673
- Address
- 94, Baiobaelli 1-ro, JECHEON, 27159
- Web
- https://www.yuyu.co.kr/ko/main/main.do
- Phone
- +82 222536600
- Auditors
- Shinwoo Accounting Corp.
Upcoming Events for 000220
Similar to 000220
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 24:17 UTC, shares in Yuyu Pharma are trading at KR₩4,710. This share price information is delayed by 15 minutes.
Shares in Yuyu Pharma last closed at KR₩4,710 and the price had moved by -6.94% over the past 365 days. In terms of relative price strength the Yuyu Pharma share price has underperformed the FTSE Developed Asia Pacific Index by -10.96% over the past year.
The overall consensus recommendation for Yuyu Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Yuyu Pharma does not currently pay a dividend.
Yuyu Pharma does not currently pay a dividend.
Yuyu Pharma does not currently pay a dividend.
To buy shares in Yuyu Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩4,710, shares in Yuyu Pharma had a market capitalisation of KR₩76bn.
Here are the trading details for Yuyu Pharma:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 000220
Based on an overall assessment of its quality, value and momentum Yuyu Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yuyu Pharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -10.93%.
As of the last closing price of KR₩4,710, shares in Yuyu Pharma were trading -5.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Yuyu Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩4,710.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Yuyu Pharma's management team is headed by:
- Seung Pil Yoo - CHM
- Robert Yu - PRE
- Jung Seon Park - MDR
- Jin Yong Song - MDR
- Han Guk Bae - OTH
- Gwang Jung Goh - OTH
- Jong Ryeol Ha - OTH
- Chang Gi Jeon - OTH
- Won Sang Yoo - OTH
- Yeong Gak Yoon - DRC
- Hyeong Moon Ahn - NID
- Seung An Kang - NID